Q-omics provides the consensus-scored PLA2G2C profile across patient tissues and cancer cell-line models. PLA2G2C expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, PLA2G2C is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, PLA2G2C RNA expression shows 16,007 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight SKCM, THCA, and GBM as cancer lineages where PLA2G2C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLA2G2C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLA2G2C survival associations across molecular data types. PLA2G2C RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLA2G2C RNA expression–survival associations across cancer types. High PLA2G2C expression shows unfavorable associations in LGG, but favorable associations in SKCM, ESCA, HNSC, UVM and BRCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for PLA2G2C RNA expression.
This table summarizes PLA2G2C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for PLA2G2C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLA2G2C shows lower tumor expression in LUSC and STAD and higher tumor expression in THCA, LUAD, KIRC and LIHC. The THCA box plot shows higher PLA2G2C RNA expression in tumor versus normal tissue (log2 FC = +0.190, t-test p < 0.001).
This table shows molecular features associated with PLA2G2C in patient tissues and cancer cell lines. In patient samples, PLA2G2C shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PLA2G2C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia.
